IE83704B1 - Novel osteoinductive factors - Google Patents

Description

Novel osteoinductive factors The present invention relates to novel proteins and processes for obtaining them. These proteins are capable of inducing cartilage and bone formation.

Bone is a highly specialized tissue characterized by an extensive matrix structure formed of fibrous bundles of the protein collagen, and proteoglycans, noncollagenous proteins, lipids and acidic proteins. The processes of bone formation and renewal/repair of bone tissue, which occur continuously throughout life, are performed by specialized cells.

Normal embryonic long bone development is preceded by formation of a cartilage model. Bone growth is presumably mediated by "osteoblasts" (bone-forming cells), while remodeling of bone is apparently accomplished by the joint activities of bone-resorbing cells, called "osteoclasts" and osteoblasts. A factor which induces bone growth in circumstances where bone is not normally formed has application in the healing of bone fractures. An osteogenic preparation may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De nova bone formation induced by an osteogenic agent would contribute to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also in cosmetic plastic surgery. Osteogenic factors may be also valuable in the treatment of periodontal disease, and in other tooth repair processes.

Repair of fractures, craniofacial defects, and periodontal defects are presently treated with a bone graft or a synthetic implant. An autograft has highest chance for success, but the trauma of surgery and the quantity of bone that can be harvested from the patient are major disadvantages. Allogenic bone grafts are also used. The availability of cadaver bone, the quality of the banked bone, and the potential spread of human disease are serious problems associated with this treatment.

Ceramics, such as hydroxylapatite, or metals are also used, but these materials are only osteoconductive, i.e. new bone is generally only formed adjacent to the implant and the normal bone.

Physiologically acceptable chemical agents (hormones/ pharmaceuticals/ growth factors) capable of inducing bone formation at a predetermined site are therefore desirable. Such agents could provide an environment to attract bone—forrning cells, stimulate growth of bone- forming cells or induce differentiation of progenitors of bone-forrning cells. A variety of osteogenic, cartilage-inducing and bone inducing factors have been described. See, e.g. European patent applications 148,155 and 169,016 for discussions thereof. However, the procedures and techniques known in the art for obtaining putative osteogenic activities are prolonged and ill—defined and the factors have been only minimally identified and poorly characterized.

Thus there remains a need in the art for the accurate chemical and physiological characterization of a highly purified osteoinductive factor of a mammalian species for use in diagnosis, research and therapy of bone formation disorders.

The present invention provides a novel protein in purified form, BMP-3, where BMP is bone morphogenic protein. This protein is characterized by peptide sequences the same as or substantially homologous to the amino acid sequences illustrated in Tables 11 A and II B below. It is capable of inducing bone formation at a predetermined site. This bone inductive factor is further characterized by biochemical and biological characteristics including activity at a concentration of 10 to lO00ng/ gram of bone in an in viva rat bone formation assay described below. The Protein of this invention may be encoded by the DNA sequences depicted in the Tables or sequences capable of hybridizing thereto under stringent conditions and coding for polypeptides with bone growth factor biological properties or other variously modified sequences demonstrating such properties.

The bone inductive factor of the invention, BMP-3, is represented by the bovine homolog bBMP-3. bBMP—3 is characterized by the DNA sequence and amino acid sequence of Table II A and B which represents the bovine genomic sequence. It is characterized by at least a portion of a peptide sequence the same or substantially the same as amino acid #1 through amino acid #175 of Table II A and B.

BMP-3 is further characterized by the ability to induce bone formation.

This bovine factor may be employed as a tool for obtaining the analogous human BMP-3 protein or other mammalian bone inductive protein. The proper characterization of this bovine bone inductive factor of the present invention provides the essential "starting point" for the method employing this sequence. The method, employing techniques known to those skilled in the art of genetic engineering, involves using the bovine DNA sequence as a probe to screen a human genomic or cDNA library; and identifying the DNA sequences which hybridize to the probes. A clone with a hybridizable sequence is plaque purified and the DNA isolated therefrom, subcloned and subjected to DNA sequence analysis. Thus, another aspect of this invention is a human protein hBMP-3, produced by this method.

Another aspect of the invention provides pharmaceutical compositions containing a therapeutically effective amount of the bone growth factor polypeptides according to the invention. These compositions may be employed in methods for treating a number of bone defects and periodontal disease. These methods according to the invention entail administering to a patient an effective amount of the novel protein BMP-3 as described herein.

Still a further aspect of the invention are DNA sequences coding on expression for a human or bovine polypeptide having the ability to induce bone formation. Such sequences include the sequence of nucleotides in a 5' to 3' direction illustrated in Tables II A and B.

Alternatively a DNA sequence which hybridizes under stringent conditions with the DNA sequence of Tables II A and B and which codes on expression for a protein having at least one bone growth factor biological property are included in the present invention. Finally, allelic variations of the sequences of Tables 11 A and B, whether such nucleotide changes result in changes in the peptide sequence or not, are also included in the present invention.

Still a further aspect of the invention is a vector containing a DNA sequence as described above in operative association with an expression control sequence. Such vector may be employed in a novel process for producing a bone growth factor polypeptide in which a cell line transformed with a DNA sequence encoding expression of a bone growth factor polypeptide in operative association with an expression control sequence therefor is cultured. This claimed process may employ a number of known cells as host cells for expression of the polypeptide.

Presently preferred cell lines are mammalian cell lines and bacterial cells.

Other aspects and advantages of the present invention will be apparent upon consideration of the following detailed description of preferred embodiments thereof.

The bone growth factor provided by the present invention is substantially free of association with other bovine or human proteins and is characterized by amino acid sequences the same as or substantially homologous to the sequences shown in Tables 11 A and B below. This growth factor is also characterized by demonstrating a biological property of a bone growth factor.

Also included in the present invention are synthetic polypeptides which wholly or partially duplicate continuous sequences of the amino acid residues of Tables II A and B. These sequences, by virtue of sharing primary, secondary, or tertiary structural and conformational characteristics with bone growth factor polypeptides of Tables 11 A and B may possess bone growth factor biological properties in common therewith. Thus, they may be employed as biologically active substitutes for naturally-occurring primate bone growth factor polypeptides in therapeutic processes.

The bone growth factor provided herein also include factors encoded by the sequences similar to those of Tables 11 A and B, but into which modifications are naturally provided or deliberately engineered.

Other specific mutations of the sequences of the bone growth factor described herein involve modifications of one or both of the glycosylation sites. The absence of glycosylation or only partial glycosylation results from amino acid substitution or deletion at one or both of the asparagine-linked glycosylation recognition sites present in the sequences of the bone growth factor shown in Tables 11 A and B.

The asparagine-linked glycosylation recognition sites comprise tripeptide sequences which are specifically recognized by appropriate cellular glycosylation enzymes. These tripeptide sequences are either asparagine—X-threonine or asparagine—X-serine, where X is usually any amino acid. A variety of amino acid substitutions or deletions at one or both of the first or third amino acid positions of a glycosylation recognition site (and/or amino acid deletion at the second position) results in non-glycosylation at the modified tripeptide sequence.

The present invention also encompasses the novel DNA sequences, free of association with DNA sequences encoding other proteinaceous materials, and coding on expression for bone growth factors. These DNA sequences include those depicted in Tables 11 A and B in a 5' to 3' direction and those sequences which hybridize under stringent hybridization conditions [see, T. Maniatis et al., Molecular Cloning (A Laboratory Manual), Cold Spring Harbor Laboratory (1982), pages 387 to 389] to the DNA sequences of Tables 11 A and B.

Similarly, DNA sequences which code for bone growth factor polypeptides coded for by the sequence of Tables 11 A and B, but which differ in codon sequence due to the degeneracies of the genetic code or allelic variations (naturally-occuring base changes in the species population which may or may not result in an amino acid change) also encode the novel growth factors described herein. Variations in the DNA sequences of Tables 11 A and B which are caused by point mutations or by induced modifications to enhance the activity, half-life or production of the polypeptides encoded thereby are also encompassed in the invention.

Another aspect of the present invention provides a novel method for producing the novel osteoinductive factors. The method of the present invention involves culturing a suitable cell or cell line, which has been transformed with a DNA sequence coding on expression for a novel bone growth factor polypeptide under the control of known regulatory sequences. Suitable cells or cell lines may be mammalian cells, such as Chinese hamster ovary cells (CHO). The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, Nature, _29_3:620- 625 (1981), or alternatively, Kaufman et al., Mol. Cell. Biol., _5_(7):l750- 1759 (1985) or Howley et al., U.S. Patent 4,419,446. Another suitable mammalian cell line, which is described in the accompanying examples, is the monkey COS—l cell line. A similarly useful mammalian cell line is the CV-l cell line.

Similarly useful as host cells suitable for the present invention are bacterial cells. For example, the various strains of E. coli (e.g., HBl0l, MCl06l and strains used in the following examples) are well-known as host cells in the field of biotechnology. Various strains of B. subtilis, Pseudomonas, other bacilli and the like may also be employed in this method.

Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention. Additionally, where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g.

Another aspect of the present invention provides vectors for use in the method of expression of these novel osteoinductive polypeptides.

Preferably the vectors contain the full novel DNA sequences described above which code for the novel factor of the invention.

Additionally the vectors also contain appropriate expression control sequences permitting expression of the bone inductive factor sequences.

Alternatively, vectors incorporating modified sequences as described above are also embodiments of the present invention and useful in the production of the bone inductive factors. The vectors may be employed in the method of transforming cell lines and contain selected regulatory sequences in operative association with the DNA coding sequences of the invention which are capable of directing the replication and expression thereof in selected host cells. Useful regulatory sequences for such vectors are known to one of skill in the art and may be selected depending upon the selected host cells. Such selection is routine and does not form part of the present invention.

A further aspect of the invention is a therapeutic composition for repairing fractures and other conditions related to bone defects or periodontal diseases. Such a composition comprises a therapeutically effective amount of the bone inductive factor protein compositions of the invention. The bone inductive factor according to the present invention may be present in a therapeutic composition in admixture with a pharmaceutically acceptable carrier or matrix. Additionally, the factor according to the present invention may be co—administered with one or more different osteoinductive factors, with which it may interact.

Further, the therapeutic composition may be combined with other agents beneficial to the treatment of the bone defect in question.

The therapeutic method includes locally administering the composition as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Preferably, the bone growth inductive factor composition would include a matrix capable of delivering the bone inductive factor to the site of bone damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of other materials presently in use for other implanted medical applications.

The bone inductive factor composition can also alternatively include other osteoinductive materials, such as hydroxylapatite, ceramics and the like. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone damage. The preparation of such physiologically acceptable protein compositions, having due regard to pH, isotonicity, stability and the like, is within the skill of the art.

The dosage regimen will be determined by the attending physician considering various factors which modify the action of such a growth factor, e. g. amount of bone weight desired to be formed, the site of bone damage, the condition of the damaged bone, the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. Generally, the dosage regimen should be in the range of approximately 10 to 105 nanograms of protein per gram of bone weight desired. Progress can be monitored by periodic assessment of bone growth and/or repair, e.g. x-rays. Such therapeutic compositions are also presently valuable for veterinary applications due to the lack of species specificity in bone inductive factors. Particularly domestic animals and thoroughbred horses are desired patients for such treatment with the bone inductive factor of the present invention.

Therapeutic amounts of the bone inductive factor of the present invention, including variants thereof as described above, may be used individually for repairing fractures and other conditions related to bone defects or peridontal diseases.

The bone inductive factor of the present invention may be used in conjunction with a variety of biomaterials which provide a theraputically suitable enviroment for the induction of bone growth.

Preferably the bone growth inductive factor compositions of the invention are used in conjunction with a matrix capable of delivering the factor composition to the site of bone damage, providing a structure for the developing bone and cartilage. It is preferred that the matrix be capable of being resorbed into the body. There are presently many different materials that are used for both hard and soft tissue replacement. The type of material used will depend on several factors and the choice is within the knowledge of those having ordinary skill in the art. The choice of material is based on, for example, biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. Similarly, the application of the osteoinductive factor will define the appropriate formulation. Potential matrices for osteoinductive factor may be biodegradable and chemically defined, such as but not limited to calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyanhydrides; biodegradable and biologically well defined, such as bone or dermal collagen, other pure proteins or extracellular matrix components; nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics; or combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics might also be altered in composition, such as in calcium—alurninate-phosphate and processing to alter for example, pore size, particle size, particle shape, and biodegradability.

As described above the dosage regimen will be determined by the attending physician considering various factors which modify the action of such a growth factor. The amount of bone that is formed is dependent on the amount and type of factor used and the type of matrix in the final compositon. The dosage regimen should be in the range of -l06ng per gram of bone weight desired. The dosage may vary with the type of matrix used in the reconstitution. The addition of other known growth factors, such as IGF l (insulin like growth factor 1), to the final composition, may also affect the dosage.

The following examples illustrate practice of the present invention in recovering and characterizing the bovine bone inductive factors, employing the bovine bone inductive factors to recover human bone inductive factor, obtaining the human factors and in expressing the bone inductive factors via recombinant techniques.

EXAMPLE I Isolation of Bovine Bone Inductive Factor Ground bovine bone powder (20-120 mesh, Helitrex) is prepared according to the procedures of M. R. Urist et al., Proc. Natl Acad. Sci Q8/_X, 70:35 11 (1973) with elimination of some extraction steps as identified below. Ten kgs of the ground powder is demineralized in successive changes of 0.6N HCl at 4°C over a 48 hour period with vigorous stirring. The resulting suspension is extracted for 16 hours at 4°C with 50 liters of 2M CaCl2 and lOmM ethylenediamine—tetraacetic acid [EDTA], and followed by extraction for 4 hours in 50 liters of 0.5M EDTA. The residue is washed three times with distilled water before its resuspension in 20 liters of 4M guanidine hydrochloride [GuCl], 20mM Tris (pH 7.4), lmM N—ethylmaleimide, lmM iodoacetamide, lmM phenylmethylsulfonyl fluorine as described in Clin. Orthop. Rel. Res., 171: 213 (l982). After 16 to 20 hours the supernatant is removed and replaced with another 10 liters of GuCl buffer. The residue is extracted for another 24 hours.

The crude GuCl extracts are combined, concentrated approximately 20 times on a Pellicon apparatus with a 10,000 molecular weight cut-off membrane, and then dialyzed in 50mM Tris, 0. lM NaCl, 6M urea (pH7.2), the starting buffer for the first column. After extensive dialysis the protein is loaded on a 4 liter DEAE cellulose column and the unbound fractions are collected.

The unbound fractions are concentrated and dialyzed against 50mM NaAc, 50mM NaCl Q3H 4.6) in 6M urea. The unbound fractions are applied to a carboxymethyl cellulose column. Protein not bound to the column is removed by extensive washing with starting buffer, and the bone inductive factor containing material desorbed from the column by 50mM NaAc, 0.25mM NaCl, 6M urea (pH 4.6). The protein from this step elution is concentrated 20- to 40- fold, then diluted 5 times with 80mM KPO4, 6M urea (pH6.0). The pH of the solution is adjusted to 6.0 with 500mM K2HP04. The sample is applied to an hydroxylapatite column (LKB) equilibrated in 80mM KPO4, 6M urea (pH6.0) and all unbound protein is removed by washing the column with the same buffer. Bone inductive factor activity is eluted with l0OmM KPO4 (pH7.4) and 6M urea.

The protein is concentrated approximately 10 times, and solid NaCl added to a final concentration of 0.15M. This material is applied to a heparin - Sepharose column equilibrated in 50mM KPO4, 150mM NaCl, 6M urea (pH7.4). After extensive washing of the column with starting buffer, a protein with bone inductive factor activity is eluted by 50mM KPO4, 700mM NaCl, 6M urea (pH7.4). This fraction is concentrated to a minimum volume, and O.4ml aliquots are applied to Superose 6 and Superose 12 columns connected in series, equilibrated with 4M GuCl, 20mM Tris (pH7.2) and the columns developed at a flow rate of 0.25n1l/rnin. The protein demonstrating bone inductive factor activity has a relative migration corresponding to approximately ,000 dalton protein.

The above fractions are pooled, dialyzed against 50mM NaAc, 6M urea (pH4.6), and applied to a Pharmacia MonoS HR column. The column is developed with a gradient to 1.0M NaCl, 50mM NaAc, 6M urea (pH4.6). Active fractions are pooled and brought to pH3.0 with % trifluoroacetic acid (TFA). The material is applied to a 0.46 x 25cm Vydac C4 column in 0.1% TFA and the column developed with a gradient to 90% acetonitrile, 0.1% TFA (31.5% acetonitrile, 0.1% TFA to 49.5% acetonitrile, 0.1% TFA in 60 minutes at lml per minute).

Active material is eluted at approximately 40-44% acetonitrile.

Aliquots of the appropriate fractions are iodinated by one of the following methods: P. J. McConahey et al., Int. Arch. Allergy, 29:185- 189 (1966); A. E. Bolton et al., Biochem J., 133:529 (1973); and D. F.

Bowen-Pope, J. Biol. Chem, 237:5161 (1982). The iodinated proteins present in these fractions are analyzed by SDS gel electro—phoresis and urea Triton X 100 isoelectric focusing. At this stage, the bone inductive factor is estimated to be approximately 10-50% pure.

E)QXMPLE II Characterization of Bovine Bone Inductive Factor A. Molecular Weight Approximately 20ug protein from Example I is lyophilized and redissolved in 1X SDS sample buffer. After 15 minutes of heating at 37°C, the sample is applied to a 15% SDS polyacrylamide gel and then electrophoresed with cooling. The molecular weight is determined relative to prestained molecular weight standards (Bethesda Research Labs). Immediately after completion, the gel lane containing bone inductive factor is sliced into 0.3cm pieces. Each piece is mashed and l.4rnl of 0. 1% SDS is added. The samples are shaken gently overnight at room temperature to elute the protein. Each gel slice is desalted to prevent interference in the biological assay. The supernatant from each sample is acidified to pH 3.0 with 10% TFA, filtered through a 0.45 micron membrane and loaded on a 0.46cm x 5cm C4 Vydac column developed with a gradient of 0.1% TFA to 0.1% TFA, 90% CH3CN.

The appropriate bone inductive factor - containing fractions are pooled and reconstituted with 20mg rat matrix. In this gel system, the majority of bone inductive factor fractions have the mobility of a protein having a molecular weight of approximately 28,000 - 30,000 daltons.

B. Isoelectric Focusing The isoelectric point of bone inductive factor activity is determined in a denaturing isoelectric focusing system. The Triton X100 urea gel system (Hoeffer Scientific) is modified as follows: 1) 40% of the ampholytes used are Servalyte 3/10; 60% are Servalyte 7-9. 2) The catholyte used is 40mM NaOH. Approximately 20 ug of protein from Example I is lyophilized, dissolved in sample buffer and applied to the isoelectrofocusing gel. The gel is run at 20 watts, 10°C for approximately 3 hours. At completion the lane containing bone inductive factor is sliced into 0.5 cm slices. Each piece is mashed in l.0ml 6M urea, 5mM Tris (pH 7.8) and the samples agitated at room temperature. The pH gradient of the gel is determined by soaking 5mm slices in 1.01111 water for over 2 hours. The samples are acidified, filtered, desalted and assayed as described above. The major portion of activity as determined in the assay described in Example III migrates in a manner consistent with a pl of 8.8 - 9.2.

C. Subunit Characterization The subunit composition of bone inductive factor is also determined. Pure bone inductive factor is isolated from a preparative % SDS gel as described above. A portion of the sample is then reduced with 5mM DTT in sample buffer and re—electrophoresed on a % SDS gel. The approximately 30kd protein yields two major bands at approximately 20kd and 18kd, as well as a minor band at 30kd. The broadness of the two bands indicates heterogeneity caused most probably by glycosylation, other post translational modification, proteolytic degradation or carbamylation.

EXAMPLE III Biological Activity of Bone Inductive Factor A rat bone formation assay according to the general procedure of Sampath and Reddi, Proc. Natl. Acad. Sci. U.S.A., 80:659l—6595 (1983) is used to evaluate the osteogenic activity of the bovine bone inductive factor of the present invention obtained in Example I. This assay can also be used to evaluate bone inductive factors of other species. The ethanol precipitation step is replaced by dialyzing the fraction to be assayed against water. The solution or suspension is then redissolved in a volatile solvent, e. g. 0.1 - 0.2 % TFA, and the resulting solution added to 20mg of rat matrix. This material is frozen and lyophilized and the resulting powder enclosed in #5 gelatin capsules. The capsules are implanted subcutaneously in the abdominal thoracic area of 21 - 49 day old male long Evans rats. The implants are removed after 7 - 14 days.

Half of each implant is used for alkaline phosphatase analysis [See, A.

H. Reddi et al., Proc. Natl Acad Sci., 69: 1601 (l972)] and half is fixed and processed for histological analysis. Routinely, lum glycolmethacrylate sections are stained with Von Kossa and acid fuschin to detect new bone mineral. Alkaline phosphatase, an enzyme produced by chondroblasts and osteoblasts in the process of matrix formation, was also measured. New cartilage and bone formation often correlates with alkaline phosphatase levels. Table I below illustrates the dose response of the rat matrix samples including a control not treated with bone inductive factor.

TABLE 1 Protein* Cartilage Alk. Phos. u/l Implanted ug 7.5 2 Not done 2.5 3 445 .7 0.83 3 77.4 0.28 0 32.5 0.00 0 31.0 *At this stage the bone inductive factor is approximately 10-15% pure.

The bone or cartilage formed is physically confined to the space occupied by the matrix. Samples are also analyzed by SDS gel electrophoresis and isoelectric focusing as described above, followed by autoradiography. Analysis reveals a correlation of activity with protein bands at 28 - 30kd and a pl 9.0. An extinction coefficient of l OD/mg- cm is used as an estimate for protein and approximating the purity of bone inductive factor in a particular fraction. In the in vivo rat bone formation assays on dilutions as described above, the protein is active in vivo at 10 to 200ng protein/ gram bone to probably greater than lug protein/ gram bone.

EXAMPLE IV Bovine Bone Inductive Factor Protein Composition The protein composition of Example IIA of molecular weight 28 — kd is reduced as described in Example IIC and digested with trypsin.

Eight tryptic fragments are isolated by standard procedures having the following amino acid sequences: Fragment1:AAFLGDIALDEEDLG Fragment2:AFQVQQAADL Fragment3:NYQDMVVEG Fragment4:STPAQDVSR Fragment5:NQEALR Fragment6:LSEPDPSHTLEE Fragment7:FDAYY Fragment8:LKPSN?ATIQSIVE A less highly purified preparation of protein from bovine bone is reduced and electrophoresed on an acrylamide gel. The protein corresponding to the 18K band is eluted and digested with trypsin.

Tryptic fragments are isolated having the following amino acid sequences: Fragment 9:SLKPSNHATIQS?V FragmentlO:SFDAYYCS?A Fragmentll:VYPNMTVESCA Fragment12:VDFADI?W Tryptic Fragments 7 and 8 are noted to be substantially the same as above Fragments 10 and 9, respectively.

A. bBMP-3 Probes consisting of pools of oligonucleotides are designed on the basis of the amino acid sequences of the tryptic Fragments 9 (Probe #3), (Probe #2) and 11 (Probe #1), and synthesized on an automated DNA synthesizer.

Probe#l:ACNGTCAT[A/G]TTNGG[A/G]TA (based on Fragment 11) Probe #2: C A [A/G] T A [A/G] T A N G C [A/G] T C [A/G] A A (based on Fragment 10) Probe #3: TG [A/G/T] ATNGTNGC [A/G] TG [A/G] TT (based on Fragment 9) A bovine genomic recombinant library is constructed as follows: Bovine liver DNA is partially digested with the restriction endonuclease enzyme Sau 3A and sedimented through a sucrose gradient. Size fractionated DNA in the range of 15-30kb is then ligated to the bacteriophage Bam HI vector EMBL3 [Frischauf et al., J. Mol. Biol., 1701827-842 (l983)]. The library is plated at 8000 recombinants per plate. Duplicate nitrocellulose replicas of the plaques are made and amplified according to a modification of the procedure of Woo et al., Proc. Natl. Acad. Sci. USA, 75:3688-91 (1978).

This recombinant bovine genomic library constructed in EMBL3 is screened by the TMAC hybridization procedure, i.e. hybridized in 3M tetramethylammonium chloride (TMAC), 0.1M sodium phosphate pH6.5, 1mM EDTA, 5X Denhardts, 0.6% SDS, 100ug/ml salmon sperm DNA at 48 degrees C, and washed in 3M TMAC, 50mM Tris pH8.0 at 50 degrees C. These conditions minimize the detection of mismatches to the 17 mer probe pool [see, Wood et al., Proc. Natl. Acad. Sci U.S.A., 8221585-1588 (l985)]. ,000 recombinants are screened in duplicate with Probe #1 which has been labeled with 32P. All recombinants which hybridized to this probe are replated for secondaries. Triplicate nitrocellulose replicas are made of the secondary plates, and amplified as described. The three sets of filters are hybridized to Probes #1, #2 and #3, again under TMAC conditions. One clone, lambda bP-819, hybridizes to all three probes and is plaque purified and DNA is isolated from a plate lysate.

Bacteriophage lambda bP—8 l 9 was deposited with the ATCC on June 16, 1987 under accession number 40344. This bP—819 clone encodes the bovine bone growth factor designated bBMP-3.

The region of bP-819 which hybridizes to Probe #1 and #3 is localized and sequenced. The partial DNA and derived amino acid sequences of this region are shown in Table II B. The amino acid sequences corresponding to tryptic Fragments 9 and 11 are underlined.

The arginine residue encoded by the AGA triplet is presumed to be the carboxy-terminus of the protein based on the presence of a stop codon (TAA) adjacent to it. The nucleic acid sequence preceding the couplet TC (positions 305-306) is presumed to be an intron (non-coding sequence) based on the presence of a consensus acceptor sequence (i.e. a pyrimidine-rich stretch, TTCTCCCTTTTCGTTCCT, followed by AG) and the presence of a stop rather than a basic residue in the appropriate position of the derived amino acid sequence.

A different region of bP-819 which hybridizes to Probe 2 is localized and sequenced. The partial DNA and derived amino acid sequences of this region are shown in Table II A. The amino acid sequences corresponding to tryptic fragments 10 and 12 are underlined. bBMP-3 is therefore characterized by the DNA and amino acid sequence of Table II A and Table II B.

EXAMPLE V Human BMP-3 TABLE II A. 383 393 403 413 (1) 428 GAGGAGGAAG CGGTCTACGG GGGTCCTTCT GCCTCTGCAG AAC AAT GAG CTT CCT GGG GCA Asn Asn Glu Leu Pro Gly Ala 473 488 GAA TAT CAG TAC AAG GAG GAT GAA GTA TGG GAG GAG AGG AAG CCT TAC AAG ACT Glu Tyr Gln Tyr Lys Glu Asp Glu Val Trp Glu Glu Arg Lys Pro Tyr Lys Thr 533 CTT CAG ACT CAG CCC CCT GAT AAG AGT AAG AAC AAA AAG AAA CAG AGG AAG GGA Leu Gln Thr Gln Pro Pro Asp Lys Ser Lys Asn Lys Lys Lys Gln Arg Lys Gly 578 593 CCT CAG CAG AAG AGT CAG ACG CTC CAG TTT GAT GAA CAG ACC CTG AAG AAG GCA Pro Gln Gln Lys Ser Gln Thr Leu Gln Phe Asp Glu Gln Thr Leu Lys Lys Ala 638 AGA AGA AAG CAA TGG ATT GAA CCC CGG AAT TGT GCC AGA CGG TAC CTT AAA GTG Arg Arg Lys Gln Trp Ile Glu Pro Arg Asn Cys Ala Arg Arg Tyr Leu Lys Val 683 698 GAC TTC GCA GAT ATT GGC TGG AGC GAA TGG ATT ATT TCC CCC AAG TCC TTC GAT Asp Phe Ala Asp Ile Gly Trp Ser Glu Trp Ile Ile Ser Pro Lys Ser Phe Asp 743 (111) 756 766 GCC TAT TAC TGC TCC GGA GCG TGC CAG TTC CCC ATG CCA AAG GTAGCCATTG TTTTTTGTCC Ala Tyr Tyr Cys Ser Gly Ala Cys Gln Phe Pro MET Pro Lys TGTCCTTCCC ATTTCCATAG ATC Ile TGT Cys CAG Gln GTG Val GTG Val AGT Ser CCA Pro GTA Val ATA Ile GAA Glu CTT Leu GTG Val AAG Lys AAA Lys AGA Arg ATG MET GTA Val TAACCTGGTG AAGAACTCAT CTGGATGCTT AACTCAATCG GCT Ala TCC Ser TAT Tyr TABLE II B.

GTG Val TCA Ser CCA Pro (112) CTAACCTGTG TTCTCCCTTT TCGTTCCTAG TCT TTG AAG CCA TCA AAT CAC GCT ACC Ser Leu Lys Pro Ser Asn His Ala Thr GGG Gly CTC Leu AAC Asn GTC Val AGC Ser ATG MET GTC Val CCT Pro ATC Ile TTA Leu ACA GTA Thr Val GGA Gly TTC Phe GAG Glu ATC Ile TTT Phe TCT Ser CCC Pro GAT Asp TGT Cys GAG Glu CCT TGC Pro Cys GAA AAC AAG Glu Asn Lys (175) TGC AGA Cys Arg GCT Ala The sequences of BMP-3 as shown in Tables 11 A and B have significant homology to the beta (B) and beta (A) subunits of the inhibins. The inhibins are a family of hormones which are presently being investigated for use in contraception. See, A. J. Mason et al., Nature, 3 1 8:659—663 (1985). To a lesser extent they are also homologous to Mullerian inhibiting substance (MIS), a testicular glycoprotein that causes regression of the Mullerian duct during development of the male embryo and transforming growth factor—beta (TGF-b) which can inhibit or stimulate growth of cells or cause them to differentiate.

Because bovine and human bone growth factor genes are presumed to be significantly homologous, oligonucleotide probes which have been shown to hybridize to the bovine DNA sequence of Table IV.A and lV.B are used to screen a human genomic library. A human genomic library (Toole et al., supra) is screened using these probes, and presumptive positives are isolated and DNA sequence obtained as described above. Evidence that this recombinant encodes a portion of the human bone inductive factor molecule relies on the bovine/human protein and gene structure homologies.

Once a recombinant bacteriophage containing DNA encoding a portion of the human BMP-3 molecule is obtained the human coding sequence is used as a probe as described above to identify a human cell line or tissue which synthesizes BMP-3. mRNA is selected by oligo (dT) cellulose chromatography and cDNA is synthesized and cloned in lambda gt10 by established techniques (Toole et al., supra).

Alternatively, the entire gene encoding this human bone inductive factor can be identified and obtained in additional recombinant clones if necessary. Additional recombinants containing further 3' or 5‘ regions of this human bone inductive factor gene can be obtained by identifying unique DNA sequences at the end(s) of the original clone and using these as probes to rescreen the human genomic library. The gene can then be reassembled in a single plasmid by standard molecular biology techniques and amplified in bacteria. The entire human BMP—3 factor gene can then be transferred to an appropriate expression vector. The expression vector containing the gene is then transfected into a mammalian cell, e.g. monkey COS cells, Where the human gene is transcribed and the RNA correctly spliced. Media from the transfected cells are assayed for bone inductive factor activity as described herein as an indication that the gene is complete. mRNA is obtained from these cells and cDNA synthesized from this mRNA source and cloned.

The procedures described above may similarly be employed to isolate other species‘ bone inductive factor of interest by utilizing the bovine bone inductive factor and/or human bone inductive factor as a probe source. Such other species‘ bone inductive factor may find similar utility in, inter alia, fracture repair.

EXAMPLE VI Expression of Bone Inductive Factors.

In order to produce bovine, human or other mammalian bone inductive factor, the DNA encoding it is transferred into an appropriate expression vector and introduced into mammalian cells by conventional genetic engineering techniques.

One skilled in the art can construct mammalian expression vectors by employing the sequence of Tables 11 A and B or other modified sequences and known Vectors, such as pCD [Okayama et al., M01. Cell Biol., 2:161- 170 (l982)] and pJL3, pJL4 [Gough et al., EMBO J ., 4:645-653 (l985)]. The transformation of these vectors into appropriate host cells can result in expression of osteoinductive factors.

One skilled in the art could manipulate the sequences of Tables HA and B by eliminating or replacing the mammalian regulatory sequences flanking the coding sequence with bacterial sequences to create bacterial vectors for intracellular or extracellular expression by bacterial cells. For example, the coding sequences could be further manipulated (e.g. ligated to other known linkers or modified by deleting non-coding sequences there—from or altering nucleotides therein by other known techniques). The modified bone inductive factor coding sequence could then be inserted into a known bacterial vector using procedures such as described in T. Taniguchi et al., Proc. Natl Acad. Sci. USA, 7725230- 5233 (1980). This exemplary bacterial vector could then be transformed into bacterial host cells and bone inductive factor expressed thereby.

For a strategy for producing extracellular expression of bone inductive factor in bacterial cells., see, e. g. European patent application EPA 177,343.

Similar manipulations can be performed for the construction of an insect vector [See, e. g. procedures described in published European patent application 155,476] for expression in insect cells. A yeast vector could also be constructed employing yeast regulatory sequences for intracellular or extracellular expression of the factors of the present invention by yeast cells. [See, e. g., procedures described in published PCT application W086/00639 and European patent application EPA 123,289].

A method for producing high levels of an osteoinductive factor of the invention from mammalian cells involves the construction of cells containing multiple copies of the heterologous bone inductive factor gene. The heterologous gene can be linked to an amplifiable marker, e. g. the dihydrofolate reductase (DHFR) gene for which cells containing increased gene copies can be selected for propagation in increasing concentrations of methotrexate (MTX) according to the procedures of Kaufman and Sharp, J. Mol. Biol., l59:601-629 (1982). This approach can be employed with a number of different cell types.

For example, a plasmid containing a DNA sequence for a bone inductive factor gene of the invention in operative association with other plasmid sequences enabling expression thereof and the DHFR expression plasmid pAdA26SV(A)3 [Kaufman and Sharp, Mol. Cell. 1, 221304 (l982)] can be co-introduced into DHFR- def1cientCHO cells, DUKX—BII, by calcium phosphate coprecipitation and transfection. DHFR expressing transforrnants are selected for growth in alpha media with dialyzed fetal calf serum, and subsequently selected for amplification by growth in increasing concentrations of MTX (sequential steps in 0.02, 0.2, 1.0 and 5uM MTX) as described in Kaufman et al., Mol Cell Biol., 5: 1750 (1983). Transformants are cloned, and biologically active bone inductive factor expression is monitored by rat bone formation assay. Bone inductive factor expression should increase with increasing levels of MTX resistance.

Similar procedures can be followed to produce other bone inductive factors.

Alternatively, the human gene is expressed directly, as described above. Active bone inductive factor may be produced in bacteria or yeast cells. However the presently preferred expression system for biologically active recombinant human bone inductive factor is stably transformed CHO cells.

EXAMPLE VII Biological Activity of Expressed Bone Inductive Factor To measure the biological activity of the expressed bone inductive factor obtained in Example VI above. The factor is partially purified on a Heparin Sepharose column. 4 ml of transfection supernatant from 1 100 mm dish is concentrated approximately 10 fold by ultrafiltration on a YM 10 membrane and then dialyzed against 20mM Tris, 0.15 M NaCL, pH 7.4 (starting buffer). This material is then applied to a 1.1 ml Heparin Sepharose column in starting buffer.

Unbound proteins are removed by an 8 ml wash of starting buffer, and bound proteins, are desorbed by a 3-4 ml wash of 20 mM Tris, 2.0 M NaCL, pH 7.4.

The proteins bound by the Heparin column are concentrated approximately 10-fold on a Centricon 10 and the salt reduced by diafiltration with 0.1% trifluoroacetic acid. The appropriate amount of this solution is mixed with 20 mg of rat matrix and then assayed for Q vivo bone and cartilage formation as previously described in Example III. A mock transfection supernatant fractionation is used as a control.

The implants containing rat matrix to which specific amounts of human BMP-3 have been added are removed from rats after seven days and processed for histological evaluation. Representative sections from each implant are stained for the presence of new bone mineral with von Kossa and acid fuschin, and for the presence of cartilage-specific matrix formation using toluidine blue. The types of cells present within the section, as well as the extent to which these cells display phenotype are evaluated.

Claims (23)

Claims: - GAA Glu CTT Leu CCT Pro AGA Arg 653 GAC Asp GCC Ala 334

1. 383 GAGGAGGAAG CGGTCTACGG GGGTCCTTCT GCCTCTGCAG TAT Tyr CAG Gln 548 CAG Gln AGA Arg TTC Phe TAT Tyr 443 CAG Gln ACT Thr CAG Gln AAG Lys GCA Ala 713 TAC Tyr 776 2 A gene encoding bovine BMP-3 comprising the following DNA sequence: TAC Tyr CAG Gln AAG Lys 608 CAA Gln GAT Asp TGC Cys 393 AAG Lys 503 CCC Pro AGT Ser TGG Trp ATT Ile TCC Ser GAG Glu CCT Pro CAG Gln ATT Ile 668 GGC Gly GGA Gly 786 TGTCCTTCCC ATTTCCATAG; 294 349 GAT Asp GAT Asp 563 ACG Thr GAA Glu TGG Trp GCG Ala and 403 458 GAA Glu AAG Lys CTC Leu CCC Pro AGC Ser 728 TGC Cys 304 GTA Val AGT Ser CAG Gln 623 CGG Arg GAA Glu CAG Gln TGG Trp 518 AAG Lys TTT Phe AAT Asn TGG Trp TTC Phe (112) CTAACCTGTG TTCTCCCTTT TCGTTCCTAG TCT TTG AAG CCA TCA AAT CAC GCT ACC Ser Leu Lys Pro Ser Asn His Ala Thr 413 GAG Glu AAC Asn GAT Asp TGT Cys 683 ATT Ile CCC Pro 364 (1) AAC AAT GAG CTT CCT GGG GCA Asn Asn Glu Leu Pro Gly Ala GAG Glu Lys 578 GAA Glu GCC Ala ATT Ile ATG MET 473 AGG Arg AAG Lys AAG Lys Lys CAG Gln ACC Thr 638 CGG Arg AGA Arg TCC Ser CCC Pro 743 CCA Pro Lys 319 428 CCT Pro TAC AAG Tyr Lys 533 CAG Gln AGG Arg AAG Lys 593 AAG Lys CTG Leu AAG Lys TAC Tyr CTT Leu AAA Lys 698 AAG TCC Lys Ser TTC Phe 756 379 488 ACT Thr GGA Gly GCA Ala GTG Val GAT Asp ATC CAG AGT ATA GTG AGA GCT GTG GGG GTC GTC CCT GGA ATC CCC GAG CCT TGC Ile Gln Ser Ile Val Arg Ala Val Gly Val Val Pro Gly Ile Pro Glu Pro Cys 394 409 424 439 TGT GTG CCA GAA AAG ATG TCC TCA CTC AGC ATC TTA TTC TTT GAT GAA AAC AAG Cys Val Pro Glu Lys MET Ser Ser Leu Ser Ile Leu Phe Phe Asp Glu Asn Lys 766 AAG GTAGCCATTG TTTTTTGTCC 454 469 484 (175) AAT GTG GTA CTT AAA GTA TAT CCA AAC ATG ACA GTA GAG TCT TGT GCT TGC AGA Asn Val Val Leu Lys Val Tyr Pro Asn MET Thr Val Glu Ser Cys Ala Cys Arg 503 513 523 533 TAACCTGGTG AAGAACTCAT CTGGATGCTT AACTCAATCG.

2. A gene encoding bovine BMP—3 having the amino acid sequence given in claim 1.

3. A gene encoding a protein exhibiting at least the property of BMP—3 to induce the formation of bone and comprising a DNA sequence: (a) which differs from a DNA sequence of claim 1 in codon sequence due to the degeneracy of the genetic code; (b) which hybridises with a DNA sequence of claim 1 or section (a), above, under stringent hybridization conditions; or (c) which represents a fragment or allelic variation of a DNA sequence of claim 1.

4. The DNA sequence of claim 3, which encodes human BMP—3.

5. The DNA sequence of claim 3 or 4, which is a genomic DNA sequence.

6. The DNA sequence of claim 3 or 4, which is a cDNA sequence.

7. A vector containing the gene or DNA sequence of any one of claims 1 to 6 in operative association with an expression control SCC11lC1'1CC.

8. A cell transformed with a vector of claim 7.

9. The cell of claim 8 which is a mammalian cell, a bacterial cell, an insect cell or a yeast cell.

10. The cell of claim 9 which is a CHO cell.

11. A protein exhibiting properties of BMP-3 which is encoded by the gene or DNA sequence of any one of claims 1 to 6.

12. A protein exhibiting properties of BMP-3 which is produced by the steps of culturing in a suitable culture medium a cell transformed with an expression vector comprising a gene or a DNA sequence of any one of claims 1 to 6, and recovering said protein from said culture medium.

13. A process for producing the protein of claim 11 or 12, comprising the steps of culturing in a suitable culture medium the cell of claim 9 and isolating said protein from said culture medium.

14. A pharmaceutical composition comprising the protein of claim 11 or 12 and a pharrnaceutically acceptable vehicle.

15. The pharmaceutical composition of claim 14, further comprising a matrix capable of delivering the composition to the site of a bone or cartilage defect and providing a structure for inducing bone or cartilage formation.

16. The pharmaceutical composition of claim 15, wherein said matrix comprises hydroxyapatite, col1agen,po1ylactic acid or tricalcium phosphate.

17. Use of a protein of claim 11 or 12 for the preparation of a pharmaceutical composition for inducing bone or cartilage formation.

18. A gene encoding a protein exhibiting properties of BMP-3 according to claim 1, substantially as hereinbefore described.

19. A Vector according to claim 7, substantially as hereinbefore described.

20. A protein according to claim 11 or 12, substantially as hereinbefore described.

21. A process according to claim 13, substantially as hereinbefore described.

22. A pharmaceutical composition according to claim 14, substantially as hereinbefore described.

23. Use according to claim 17, substantially as hereinbefore described. ANNE RYAN & CO., Agents for the Applicants.